SITABLU DM. Tablets
Sitagliptin 100 mg + Dapagliflozin 10 mg + Metformin 500 mg
Triple Power Control for Effective Diabetes Management
SITABLU DM. offers a powerful triple combination therapy designed for patients where monotherapies fail to provide optimal glycemic control. With Sitagliptin, Dapagliflozin, and Metformin, this formulation delivers comprehensive diabetes and cardiovascular management benefits.
Key Benefits:
✅ Ensures Triple Mechanism of Action for Better Glycemic Control
✅ Helps Manage Type-2 Diabetes & Cardiovascular Risk Together
✅ Offers Weight-Neutral & Lipid-Neutral Effects
✅ Significantly Improves HbA1c Levels
✅ Well Tolerated with Low Risk of Hypoglycemia or Edema
✅ Enhances β-Cell Function & Responsiveness
How SITABLU DM Works:
💊 Dapagliflozin (SGLT2 Inhibitor)
-
Increases glucose excretion via urine
-
Reduces blood sugar effectively
-
Minimizes risk of hypoglycemia and DKA (Diabetic Ketoacidosis)
💊 Sitagliptin + Metformin
-
Improves pancreatic islet responsiveness to glucose
-
Supports β-cell function in hyperglycemic states
-
Long-term preservation of insulin-secreting cells
-
Ideal for T2DM with minimal side effects
Indications:
🔹 Type-2 Diabetes Mellitus (T2DM)
🔹 Diabetic Patients with Cardiovascular Comorbidities
Why Choose SITABLU DM?
Because it’s more than just diabetes control—it’s a superior, strategic solution for long-term metabolic and cardiac health.
SITABLU DM. – The Superior Diabetes Control